Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2022-03-04 00:00:00 ET · period of report 2022-01-01 · accession 0001209191-22-016537 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-04 | 2022-01-01 | NTLA | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | — | +7,848 | 727.2K | +1% | — |
| D | 2022-03-04 | 2022-03-01 | NTLA | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +41.0K | 765.6K | +6% | $0 |
| D | 2022-03-04 | 2022-01-01 | NTLA | LEONARD JOHN M | Pres, CEO, Dir | S - Sale+OE | $112.26 | -2,493 | 724.7K | -0.3% | -$279.9K |
| D | 2022-03-04 | 2022-01-01 | NTLA | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | $0.00 | -7,848 | 23.5K | -25% | $0 |
| D | 2022-03-04 | 2022-03-01 | NTLA | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +59.9K | 59.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-01 | M | A | 7,848 | — | 727,153 | D | — | — | (F1) Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
| 2 | Common | Common Stock | 2022-03-01 | A | A | 40,990 | $0.00 | 765,650 | D | — | — | (F3) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| 3 | Common | Common Stock | 2022-01-01 | S | D | 2,493 | $112.26 | 724,660 | D | — | — | |
| 4 | Derivative | Restricted Stock Unit | 2022-01-01 | M | D | 7,848 | $0.00 | 23,546 | D | — · 2022-01-01 to 2031-03-02 | 7,848 Common Stock | (F1) Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. (F5) On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. |
| 5 | Derivative | Stock Option (right to buy) | 2022-03-01 | A | A | 59,941 | $0.00 | 59,941 | D | $79.85 · — to 2032-02-28 | 59,941 Common Stock | (F6) This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |